The U.S. Department of Veterans Affairs (VA) awarded a $15.6 million multiple-award Federal Supply Schedule (FSS-61-IB) contract and a $3.1 million single-award Blanket Purchase Agreement (BPA) to Recordati Rare Diseases Inc., a foreign-owned, for-profit pharmaceutical manufacturer. These indefinite-delivery vehicles allow the VA to efficiently procure Recordati's specialized orphan drug offerings, including treatments for rare diseases such as Cushing's disease, acromegaly, hyperammonemia, and homocystinuria.
The FSS-61-IB contract has a five-year period of performance from April 2021 to April 2026, while the BPA runs from July 2021 to July 2025. The contracts do not have any set-aside designations, reflecting the specialized nature of Recordati's rare disease pharmaceutical products. Through these IDVs, the VA can consistently access Recordati's portfolio of critical medications, including Signifor LAR, Isturisa, Carbaglu, Cystadane, and Cystadrops, to support comprehensive healthcare services for veterans nationwide, primarily through the VA's Veterans Integrated Service Networks (VISNs) 5 and 20.
Generated 1/17/25, 9:05 AM